9 Oct 2026 · 12 min
GLP-1 Shakeups and Airline Emergency Kit Upgrades
Friday, October 9, 2026 In today's episode, Dr. Will Flanary (@drglaucomflecken) & Adam Rose (@adjoro) cover Phase 3 results for retatrutide with up to 28.3% average weight loss at 80 weeks. They explain dosing, tolerability and what remains unproven for heart and kidney outcomes and how retatrutide compares with current GLP-1 options. They also break down a federal proposal to modernize airline emergency kits around nine life threatening categories with airline level discretion. Plus: they discuss a growing pediatric heart valve, the return of Doc, Best Medicine, Chicago Med and Grey’s…






